异动解读｜维立志博-B盘中上涨5.54%，ESMO突破性摘要入选叠加前日超跌反弹

行情直击09-23 13:11

9月23日，维立志博-B盘中上涨5.54%，报57.15港元/股，成交额6776.29万港元。消息面上，公司此前公告核心产品维利信单药治疗晚期肺外神经内分泌癌的关键注册性IIb期研究入选ESMO最新突破摘要（LBA），并获优选口头报告展示资格，将于10月26日进行展示，标志着该研究具备重大临床价值。

前一交易日股价曾因股份激励平台南京礼至以均价63.69港元减持约85.91万股引发获利回吐，单日下跌5.59%。在积极临床催化剂未变的背景下，叠加大摩上调评级至"增持"、目标价93港元，里昂维持116.9港元目标价及"跑赢大市"评级，短期超跌后买盘回补推动股价反弹。

（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohunote.com/m/news/1150006290?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-09-23 13:11","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1150006290","market":"hk","top_or_hot":-1,"title":"异动解读｜维立志博-B盘中上涨5.54%，ESMO突破性摘要入选叠加前日超跌反弹","media":"行情直击","content":"<p><p>9月23日，维立志博-B盘中上涨5.54%，报57.15港元/股，成交额6776.29万港元。消息面上，公司此前公告核心产品维利信单药治疗晚期肺外神经内分泌癌的关键注册性IIb期研究入选ESMO最新突破摘要（LBA），并获优选口头报告展示资格，将于10月26日进行展示，标志着该研究具备重大临床价值。</p><p>前一交易日股价曾因股份激励平台南京礼至以均价63.69港元减持约85.91万股引发获利回吐，单日下跌5.59%。在积极临床催化剂未变的背景下，叠加大摩上调评级至\"增持\"、目标价93港元，里昂维持116.9港元目标价及\"跑赢大市\"评级，短期超跌后买盘回补推动股价反弹。</p><p>（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>异动解读｜维立志博-B盘中上涨5.54%，ESMO突破性摘要入选叠加前日超跌反弹</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n异动解读｜维立志博-B盘中上涨5.54%，ESMO突破性摘要入选叠加前日超跌反弹\n</h2>\n\n<h4 class=\"meta\">\n\n2026-09-23 13:11 北京时间&nbsp;&nbsp;&nbsp;<strong>行情直击</strong>\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>9月23日，维立志博-B盘中上涨5.54%，报57.15港元/股，成交额6776.29万港元。消息面上，公司此前公告核心产品维利信单药治疗晚期肺外神经内分泌癌的关键注册性IIb期研究入选ESMO最新突破摘要（LBA），并获优选口头报告展示资格，将于10月26日进行展示，标志着该研究具备重大临床价值。前一交易日股价曾因股份激励平台南京礼至以均价63.69港元减持约85.91万股引发获利回吐，单日下跌...</p>\n\n<a href=\"\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"09887","symbol_name":"维立志博-B","start_time":0,"source_url":"","article_id":"1150006290","we_media_id":"1059448697","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1150006290","pubTimestamp":1790140312,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"行情直击","introduction":"个股异动一手消息解读","home_visible":1,"id":"1059448697","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"9月23日，维立志博-B盘中上涨5.54%，报57.15港元/股，成交额6776.29万港元。消息面上，公司此前公告核心产品维利信单药治疗晚期肺外神经内分泌癌的关键注册性IIb期研究入选ESMO最新突破摘要，并获优选口头报告展示资格，将于10月26日进行展示，标志着该研究具备重大临床价值。前一交易日股价曾因股份激励平台南京礼至以均价63.69港元减持约85.91万股引发获利回吐，单日下跌5.59%。","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"09887":"维立志博-B"},"translate_title":"Analysis of Unusual Movements | Weili Zhibo-B rose 5.54% intraday, with ESMO breakout summary included, coupled with the previous day's oversold rebound.","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"09887":1},"content_text":"9月23日，维立志博-B盘中上涨5.54%，报57.15港元/股，成交额6776.29万港元。消息面上，公司此前公告核心产品维利信单药治疗晚期肺外神经内分泌癌的关键注册性IIb期研究入选ESMO最新突破摘要（LBA），并获优选口头报告展示资格，将于10月26日进行展示，标志着该研究具备重大临床价值。前一交易日股价曾因股份激励平台南京礼至以均价63.69港元减持约85.91万股引发获利回吐，单日下跌5.59%。在积极临床催化剂未变的背景下，叠加大摩上调评级至\"增持\"、目标价93港元，里昂维持116.9港元目标价及\"跑赢大市\"评级，短期超跌后买盘回补推动股价反弹。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1150006290","isCrawlerRequest":true}